0a4a9b5b-90d9-4789-af04-f931433808c1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 63.7043121149897
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.290
- WNT_BETA_CATENIN_SIGNALING+0.150
- INTERFERON_GAMMA_RESPONSE+0.130
- BILE_ACID_METABOLISM+0.090
- ESTROGEN_RESPONSE_EARLY+0.080
- OXIDATIVE_PHOSPHORYLATION+0.070
- UNFOLDED_PROTEIN_RESPONSE+0.070
- UV_RESPONSE_UP+0.070
- MYC_TARGETS_V2+0.060
- DNA_REPAIR+0.050
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- UV_RESPONSE_DN-0.330
- TGF_BETA_SIGNALING-0.320
- TNFA_SIGNALING_VIA_NFKB-0.320
- E2F_TARGETS-0.290
- G2M_CHECKPOINT-0.280
- IL2_STAT5_SIGNALING-0.250
- KRAS_SIGNALING_UP-0.240
- MITOTIC_SPINDLE-0.240
- HYPOXIA-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088854 | — | — | 0.835 |
| 2 | 6ca5eb09-d104-4305-b3ec-4d6e8a0c2850 | — | — | 0.807 |
| 3 | SRR10899977 | — | — | 0.794 |
| 4 | 20040020.LumA | — | B | 0.790 |
| 5 | SRR2755094 | — | — | 0.787 |
| 6 | SJEPD019_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.781 |
| 7 | TCGA-PL-A8LX-01A-11R-A41B-07 | — | B | 0.779 |
| 8 | TCGA-ZF-A9R5-01A-12R-A42T-07 | — | — | 0.767 |
| 9 | SRR35579841 | — | B | 0.752 |
| 10 | TCGA-E9-A1R2-01A-11R-A14D-07 | — | B | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.010 | Idelalisib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |